Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Variant‐specific discrepancy when quantitating BCR‐ABL1 e13a2 and e14a2 transcripts using the Europe Against Cancer qPCR assay

15 Apr 2019

Abstract excerpt

OBJECTIVE: Molecular monitoring of treatment response in patients with chronic myelogenous leukemia is performed using the Europe Against Cancer (EAC) qPCR assay using the International Scale (IS). The assay amplifies both e13a2 and e14a2 BCR-ABL1 transcript variants. Observing distinct variant-dependent amplification curves during qPCR, we aimed to determine if this affected quantitation of BCR-ABL1. METHODS: We...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acute Lymphoblastic Leukemia research
Share to Acute Myeloid Leukemia Research
Share to Chronic Myeloid Leukemia Treatments

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 30985947
DOI: 10.1111/ejh.13238

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 10 closest

Variant‐specific discrepancy when quantitating BCR‐ABL1 e13a2 and e14a2 transcripts using the Europe Against Cancer qPCR assayPMID 30985947Read ↗

Impact of BCR::ABL1 transcript type on RT-qPCR amplification performance and molecular response to therapySemantic proximity Read ↗

Distinct characteristics of e13a2 versus e14a2 BCR-ABL1 driven chronic myeloid leukemia under first-line therapy with imatinib.Semantic proximity Read ↗

Assessment of individual molecular response in chronic myeloid leukemia patients with atypical BCR-ABL1 fusion transcripts: recommendations by the EUTOS cooperative networkSemantic proximity Read ↗

Prevalence and outcomes of uncommon BCR ‐ ABL 1 fusion transcripts in patients with chronic myeloid leukaemia: data from a single centreSemantic proximity Read ↗

Prognostic Implication of BCR-ABL Fusion Transcript Variants in Chronic Myeloid Leukemia (CML) Treated with Imatinib. A First of Its Kind Study on CML Patients of KashmirSemantic proximity Read ↗

Improved Inter-Lab Precision After CML International Scale Adoption: a 15-year history of BCR::ABL1 Proficiency TestingSemantic proximity Read ↗

RT-qPCR and RT-Digital PCR: A Comparison of Different Platforms for the Evaluation of Residual Disease in Chronic Myeloid LeukemiaSemantic proximity Read ↗

Chronic myeloid leukemia patients with the e13a2 BCR-ABL fusion transcript have inferior responses to imatinib compared to patients with the e14a2 transcriptSemantic proximity Read ↗

Standardization and quality control studies of ‘real-time’ quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia – A Europe Against Cancer ProgramSemantic proximity Read ↗

Comparison of Droplet Digital PCR versus qPCR Measurements on the International Scale for the Molecular Monitoring of Chronic Myeloid Leukemia Patients.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.